Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Evaxion Biotech ( (EVAX) ) just unveiled an announcement.
On March 5, 2026, Evaxion A/S reported a brief technical delay in filing and publishing its 2025 annual report, which had been scheduled before the opening of the Nasdaq Capital Market that day. The company emphasized that the report itself was finalized as planned and that the issue stemmed from external vendors handling regulatory filing requirements, rather than from any underlying financial or operational problems.
As a result of the filing delay, Evaxion rescheduled its planned conference call and webcast from March 5 to March 6, 2026, while maintaining the same format for investor access via phone and webcast. The minor postponement highlights the company’s reliance on third-party vendors for regulatory processes but does not appear to signal any change in business fundamentals, limiting the immediate impact for shareholders and other stakeholders to a short-term shift in the investor communications timetable.
The most recent analyst rating on (EVAX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
The score is held back primarily by weak financial fundamentals (ongoing losses, negative free cash flow, and balance sheet instability) and bearish technicals. Offsetting these, the latest earnings call was notably positive due to the MSD deal extending runway and strong EVX-01 clinical updates, while valuation support is limited given the negative P/E and no dividend.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion A/S is a clinical-stage TechBio company based in Denmark that develops novel vaccines using its proprietary, clinically validated AI-Immunology platform. The company focuses on both personalized and off-the-shelf cancer vaccines as well as prophylactic vaccines for infectious diseases, targeting high unmet medical needs across the immuno-oncology and infectious disease markets.
Average Trading Volume: 74,590
Technical Sentiment Signal: Strong Sell
Current Market Cap: $19.71M
Learn more about EVAX stock on TipRanks’ Stock Analysis page.